Results
1
-
10
of
119
<
1
2
3
...
11
12
>
Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D.
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-na?ve patients with HIV-1 infection.
,
Clinical drug investigation
[PubMed: 24557728]
[DOI: 10.1007/s40261-014-0175-4]
Kunimoto Y; Yasui H; Touda N; Miyamoto A; Okazaki M; Nakata H; Noda N; Ikeda H; Hayashi T; Takahashi S; Shinomura Y; Ishida T.
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
,
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
[PubMed: 23053505]
[DOI: 10.1007/s10156-012-0488-2]
Kis O; Zastre JA; Hoque MT; Walmsley SL; Bendayan R.
Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.
,
Pharmaceutical research
[PubMed: 23224979]
[DOI: 10.1007/s11095-012-0942-y]
Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD.
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
,
Clinical pharmacokinetics
[PubMed: 23044523]
[DOI: 10.1007/s40262-012-0012-y]
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S.
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
,
European journal of clinical pharmacology
[PubMed: 17665183]
[DOI: 10.1007/s00228-007-0344-y]
Schmid S; Opravil M; Moddel M; Huber M; Pfammatter R; Keusch G; Ambuhl P; Wuthrich RP; Moch H; Varga Z.
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
,
Virchows Archiv : an international journal of pathology
[PubMed: 17464512]
[DOI: 10.1007/s00428-007-0418-3]
Dailly E; Tribut O; Tattevin P; Arvieux C; Perr? P; Raffi F; Jolliet P.
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
,
European journal of clinical pharmacology
[PubMed: 16763827]
[DOI: 10.1007/s00228-006-0122-2]
Josephson F; Andersson MC; Flamholc L; Gissl?n M; Hagberg L; Ormaasen V; S?nnerborg A; Vesterbacka J; B?ttiger Y.
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na?ve HIV-1 infected patients.
,
European journal of clinical pharmacology
[PubMed: 19967342]
[DOI: 10.1007/s00228-009-0763-z]
Josephson F; Bertilsson L; B?ttiger Y; Flamholc L; Gissl?n M; Ormaasen V; S?nnerborg A; Diczfalusy U.
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
,
European journal of clinical pharmacology
[PubMed: 18458892]
[DOI: 10.1007/s00228-008-0492-8]
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
,
European Journal of Clinical Pharmacology
[DOI: 10.1007/s00228-009-0767-8]
<
1
2
3
...
11
12
>